PEN241115P280000
- 60.30
- 0.000.00%
Penumbra Newsroom
Penumbra, Inc.'s (NYSE:PEN) Earnings Haven't Escaped The Attention Of Investors
There May Be Some Bright Spots In Penumbra's (NYSE:PEN) Earnings
Penumbra Reveals Positive Data for Algorithm-assisted Thrombectomy Tech
How Is The Market Feeling About Penumbra?
Truist Financial Maintains Penumbra(PEN.US) With Buy Rating, Announces Target Price $240
Here's Why Penumbra (PEN) Is a Strong Momentum Stock
Penumbra To Present New Late Breaking Data Show Patients Treated With Computer Assisted Vacuum Thrombectomy Technology For Pulmonary Embolism Experience Shorter Hospital Stays And Fewer Complications Compared To Other Treatment Options At The VIVA...
Express News | New Late Breaking Data Show Patients Treated With Penumbra's Computer Assisted Vacuum Thrombectomy Technology for Pulmonary Embolism Experience Shorter Hospital Stays and Fewer Complications Compared to Other Treatment Options
Analysts Conflicted on These Healthcare Names: Penumbra (PEN), Kymera Therapeutics (KYMR) and NovoCure (NVCR)
Penumbra (PEN) Receives a Buy From BTIG
Implied Volatility Surging for Penumbra (PEN) Stock Options
Penumbra's Strong Q3 2024 Performance and Future Growth Prospects Justify Buy Rating by William Plovanic
Express News | Penumbra Inc : Canaccord Genuity Raises Target Price to $260 From $235
Penumbra, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
A Quick Look at Today's Ratings for Penumbra(PEN.US), With a Forecast Between $232 to $248
Needham Reiterates Hold on Penumbra
Penumbra Q3 Earnings Beat, Margins Expand, Stock Up in After Market
Penumbra Is Maintained at Outperform by Baird
Baird Maintains Outperform on Penumbra, Raises Price Target to $248
Penumbra, Inc. (PEN) Q3 2024 Earnings Call Transcript Summary